Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients

Imafuku, Keisuke; Yoshino, Koji; Yamaguchi, Kei; Tsuboi, Satoshi; Ohara, Kuniaki; Hata, Hiroo

Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients

Imafuku, Keisuke; Yoshino, Koji; Yamaguchi, Kei et al.

Case reports in oncology, 2017, 10(1), 290-295

Permalink : https://hdl.handle.net/2115/67551

このアイテムのアクセス数:685件（2026-10-12 20:31 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
461576	pdf	630 KB	512

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/67551
タイトル	Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients
著者	Imafuku, Keisuke ; Yoshino, Koji ; Yamaguchi, Kei ; Tsuboi, Satoshi ; Ohara, Kuniaki ; Hata, Hiroo
著者名 Imafuku, Keisuke
著者名 Yoshino, Koji
著者名 Yamaguchi, Kei
著者名 Tsuboi, Satoshi
著者名 Ohara, Kuniaki
e-Rad_Researcher 90399915 著者名 Hata, Hiroo
言語	英語
キーワード	Malignant melanoma
	Vemurafenib
	Brain metastasis
	Drug resistance
	BRAF mutation
	Heterogeneous lesion
	LDH
発行日	2017-04-24
出版者	Karger
収録物名	Case reports in oncology
巻(号)	10(1)
ページ	290-295
抄録	Vemurafenib is an inhibitor of the BRAF mutation and has been approved by the Food and Drug Administration as a treatment option for patients with unresectable melanoma without brain metastasis. In the literature, vemurafenib has been reported to be also effective against brain metastasis. We encountered 3 cases with brain metastasis on vemurafenib therapy. In these cases, vemurafenib was clinically effective against metastatic lesions other than those in the brain. The brain lesions developed after the metastatic lesion had occurred. Therefore, we assume that the melanomas of the patients acquired resistance against vemurafenib. The brain metastases were treated with the cyberknife. Patients 1 and 2 without LDH elevation are still alive, but patient 3 with abnormal LDH elevation died despite the treatment. We need to carefully follow patients on vemurafenib therapy because brain metastasis can suddenly occur even if the metastatic lesion has decreased clinically. The therapeutic effect of vemurafenib against brain metastasis is poor in cases with LDH elevation.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial 4.0 International
権利情報	The final, published version of this article is available at http://www.karger.com/?doi=10.1159/000461576
PISSN	1662-6575
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1159/000461576